Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012–2018)

Abstract

Background: Statin remains a mainstay in the prevention and treatment of cardiovascular diseases. Statin utilization has evolved over time in many countries, but data on this topic from China are quite limited. This study aimed to investigate the changing trends of statins prescription, as well as detail the statin utilization through a successive longitudinal study. Methods: The prescription database was established based on electronic health records retrieved from the hospital information system of Jinshan Hospital, Fudan University from January 2012 to December 2018 in Shanghai, China. The prescription rates and proportions of different statin types and doses among all patients were examined. Subanalyses were performed when stratifying the patients by age, gender, dose intensity, and preventative intervention. Results: During the study period, a total of 51,083 patients, who were prescribed for statins, were included in this study (mean [SD] age, 59.78 [±13.16] years; 53.60% male, n = 27, 378). The overall statins prescription rate in which patients increased from 2012 (1.24, 95% CI: 1.21-1.27%) to 2018 (3.16, 95% CI: 3.11-3.20%), P < 0.001. Over 90% of patients were given a moderate dose of statins. Patients with a history of coronary and cerebrovascular events (over 32%) were more likely to be prescribed with statins for preventative intervention. Furthermore, our study has witnessed a significant rise in statin therapy in primary and secondary prevention. Conclusions: In conclusion, statins were frequently prescribed and steadily increased over time in our study period. There were also changes in statin drug choices and dosages. A coordinated effort among the patient, clinical pharmacist, stakeholders and health system is still needed to improve statin utilization in clinical practice in the future.

Low-Density Lipoprotein Cholesterol and the Risk of Rheumatoid Arthritis: A Prospective Study in a Chinese Cohort

“…While we excluded participants who were taking lipid-lowering medications at baseline and during follow-up, we cannot exclude the possibility of under-reporting medication use. We do not expect that this could substantially impact our results, as the prevalence of lipid-lowering medication use in China is low [ 26 , 27 ]. It was also not possible to account for other important RA risk factors not measured in this study, including family history and exposure to silica dust [ 28 ].…”

Diagnosis of Statin-Induced Necrotizing Myopathy: Contribution of Anti-HMGCR Antibodies

“…Statins competitively inhibit HMGCR and have a well-established role in the secondary prevention of cardiovascular events. 3 However, clinical data suggests that the adverse reactions of statins may affect at least 30% of patients. 4 Among the several possible adverse reactions, statin-associated myopathy is the most common, with anti-HMGCR IMNM being the most severe subtype.…”

Long-Term Effect of Zhenzhu Tiaozhi Capsule (FTZ) on Hyperlipidemia: 2-Year Results from a Retrospective Study Using Electronic Medical Records

“…In China, commonly used lipid-lowering drugs include statins [ 10 ], fibrates [ 11 ], Xuezhikang (a red yeast rice dietary supplement) [ 12 ], and other traditional Chinese medicine (TCM) compounds [ 13 , 14 ]. Statins are widely used to treat hyperlipidemia and atherosclerosis and are beneficial for primary and secondary prevention of CHD [ 15 ].…”